Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dasatinib in Early Stage NSCLC
NCT00564876Phase 2Terminated
- Sponsor
- Duke University
- Start
- Nov 2007
- Primary completion
- Sep 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Nov 2007; status: terminated.
02
Drugs
dasatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00564876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00564876.